Inavolisib-Based Therapy in <i>PIK3CA</i> -Mutated Advanced Breast CancerNicholas C. Turner, Komal Jhaveri, Huiping Li et al.|New England Journal of Medicine|2024Cited by 235
Overall Survival with Inavolisib in <i>PIK3CA</i> -Mutated Advanced Breast CancerKomal Jhaveri, Nicholas C. Turner, Seock‐Ah Im et al.|New England Journal of Medicine|2025Cited by 79
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancerMaxwell R. Lloyd, Seth A. Wander, Komal Jhaveri et al.|Nature Reviews Clinical Oncology|2024Cited by 55
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?Chiara Corti, Carmen Criscitiello, Carmine De Angelis et al.|Cancer Treatment Reviews|2023Cited by 54
First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast CancerTimothy A. Yap, Komal Jhaveri|Clinical Cancer Research|2025Cited by 12